Prescribing Performance Post-Acute Coronary Syndrome Using a Composite Medication Indicator: ANZACS-QI 24 - 15/10/20
Résumé |
Background |
Guidelines previously recommended use of dual antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) and beta blockers (five classes of drugs) in patients without contraindications or intolerance after acute coronary syndrome (ACS). However, recent guidelines have taken a more nuanced view regarding the use of ACEI/ARB and beta blockers. Our aim was to develop a composite post-discharge medication indicator, based on available evidence, to support quality improvement.
Methods |
4,112 consecutive post-ACS patients who underwent coronary angiography and left ventricular ejection fraction (LVEF) assessment in 2015–16 were recorded in the All New Zealand ACS Quality Improvement (ANZACS-QI) registry. Patients receiving coronary artery bypass grafting were excluded. Three composite indicator algorithms that took into account known contraindications/intolerances were compared across NZ District Health Boards (DHBs):
1. | Five-drug-class indicator: aspirin, a second antiplatelet agent, statin, ACEI/ARB and a beta blocker. |
2. | An indicator based on the 2016 National Heart Foundation of Australia & Cardiac Society of NZ and Australia recommendations (NHFA/CSANZ indicator): aspirin, a second antiplatelet agent and a statin. Those with high-risk features (LVEF<40%, clinical heart failure, anterior myocardial infarct, diabetes or hypertension) should receive an ACEI/ARB and those with LVEF<40% a beta blocker. |
3. | ANZACS-QI modified NHFA/CSANZ indicator: aspirin, a second antiplatelet agent, statin and an ACEI/ARB (four classes), and those with LVEF<40% a beta blocker (five classes). |
Results |
Overall and individual DHB performance was highest (74%, DHB range 52–84%) when reported using the NHFA/CSANZ indicator, and slightly lower (69%, DHB range 48–78%) on the ANZACS-QI indicator. Performance was lowest using the older five-drug-class indicator (65%, DHB range 48–77%).
Conclusions |
We have developed a composite post-discharge medication indicator appropriate for use in identifying gaps in evidence-based management across NZ, which is now being reported regularly to DHBs.
Le texte complet de cet article est disponible en PDF.Keywords : Acute coronary syndromes, Secondary prevention, Registries, Quality improvement
Plan
Vol 29 - N° 6
P. 824-834 - juin 2020 Retour au numéro
Article précédent
- The Impact of Out-of-Hours Presentation on Clinical Outcomes in ST-Elevation Myocardial Infarction
- Sinjini Biswas, Angela Brennan, Stephen J. Duffy, Nick Andrianopoulos, William Chan, Antony Walton, Samer Noaman, James A. Shaw, Andrew Ajani, David J. Clark, Melanie Freeman, Chin Hiew, Ernesto Oqueli, Jeffrey Lefkovits, Christopher M. Reid, Dion Stub
- Using Coronary Artery Calcium Scoring as Preventative Health Tool to Reduce the High Burden of Cardiovascular Disease in Indigenous Australians
- Hannah R. Kempton, Timothy Bemand, Nikki K. Bart, Joseph J. Suttie
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?